Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Marky1on Jan 09, 2021 7:30am

366 Views

Post# 32260669

RPTX. Repare Therapeutics

Remember in a BioPub interview it was mentioned about 2 companies that were trading on the Nasdaq and were In preclinical stage study

Dan wrote me and told me one of the names, out of Montreal

Company is called Repare...They have a 1.6B$ Market Cap and are only I'm preclinical..Thus they have an 85% chance of failing..The market that they are targeting is relatively small compared to the untold Billions that 346 is targeting...and being a P3 company means that we have an 85% chance of succeeding

Come on Dan! Her us on the NASDAQ ASAP !

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario